Next Article in Journal
Genetic and Phenotypic Analyses of a Papaver somniferum T-DNA Insertional Mutant with Altered Alkaloid Composition
Next Article in Special Issue
Receptor and Channel Heteromers as Pain Targets
Previous Article in Journal
DNA Methylation as Clinically Useful Biomarkers—Light at the End of the Tunnel
Previous Article in Special Issue
New Strategies to Develop Novel Pain Therapies: Addressing Thermoreceptors from Different Points of View
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2012, 5(2), 114-132;

TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception

Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA
IteraMed L.L.C., Doylestown, PA 18902, USA
Ariel Pharmaceuticals, Broomfield, CO 80021 USA
Neuroscience Education Institute, University of California San Diego, Carlsbad, CA 92008, USA
Author to whom correspondence should be addressed.
Received: 18 November 2011 / Revised: 18 January 2012 / Accepted: 26 January 2012 / Published: 2 February 2012
(This article belongs to the Special Issue Emerging Pain Targets and Therapy)
View Full-Text   |   Download PDF [473 KB, uploaded 2 February 2012]


In the last decade, considerable evidence as accumulated to support the development of Transient Receptor Potential Vanilloid 1 (TRPV1) antagonists for the treatment of various chronic pain conditions. Whereas there is a widely accepted rationale for the development of TRPV1 antagonists for the treatment of various inflammatory pain conditions, their development for indications of chronic pain, where conditions of tactical, mechanical and spontaneous pain predominate, is less clear. Preclinical localization and expression studies provide a firm foundation for the use of molecules targeting TRPV1 for conditions of bone pain, osteoarthritis and neuropathic pain. Selective TRPV1 antagonists weakly attenuate tactile and mechanical hypersensivity and are partially effective for behavioral and electrophysiological endpoints that incorporate aspects of spontaneous pain. While initial studies with TRPV1 antagonist in normal human subjects indicate a loss of warm thermal perception, clinical studies assessing allelic variants suggests that TRPV1 may mediate other sensory modalities under certain conditions. The focus of this review is to summarize the current perspectives of TRPV1 for the treatment of conditions beyond those with a primary thermal sensitivity. View Full-Text
Keywords: allelic variants; chronic pain; mechanotransduction; neuropathic pain; osteoarthritis; Transient Receptor Potential Vanilloid 1 (TRPV1) allelic variants; chronic pain; mechanotransduction; neuropathic pain; osteoarthritis; Transient Receptor Potential Vanilloid 1 (TRPV1)
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Brandt, M.R.; Beyer, C.E.; Stahl, S.M. TRPV1 Antagonists and Chronic Pain: Beyond Thermal Perception. Pharmaceuticals 2012, 5, 114-132.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top